This filing contains no new hard data or financial information — the qualitative update alone is unlikely to sustain positive momentum given the company's micro-cap status and history of negative post-filing returns. Monitor for actual dose-escalation data, enrollment numbers, or any financing announcement as the next catalysts.
Price Chart
Executive Summary
Clearmind Medicine filed a 6-K with a press release reporting positive early investigator feedback from its ongoing Phase I/IIa trial of CMND-100 (MEAI) for Alcohol Use Disorder. The investigators highlighted a favorable early safety profile, no hallucinogenic effects, and smooth recruitment — all qualitative, non-quantitative updates. This is a routine clinical-stage pipeline update for a sub-$2M market cap company with no financial figures or hard data endpoints reported.
Key Facts
- Press release dated July 13, 2026, reports positive early qualitative feedback from investigators of the ongoing CMND-100 (MEAI) Phase I/IIa first-in-human trial for Alcohol Use Disorder.
- Investigators from Yale and Johns Hopkins noted a promising early safety profile with no meaningful adverse effects or cardiac concerns observed to date.
- The compound is described as non-hallucinogenic, potentially enabling a simpler treatment model without intensive monitoring.
- No quantitative data, enrollment numbers, dosing details, or financial figures were disclosed.
Financial Impact
No financial impact disclosed; qualitative clinical update only.
Risk Factors
- No quantitative trial data or endpoints reported — all updates are qualitative investigator commentary.
- Clinical-stage biotech with no approved products or revenue; financing and dilution risk remain high.
- Forward-looking statements regarding broader MEAI applications and potential treatments are speculative with no data support.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-077542 |
| Document: ea0297831-6k_clearmind.htm | 0001213900-26-077542 |
| Document: 0001213900-26-077542-index-headers.html | 0001213900-26-077542 |
| Document: 0001213900-26-077542-index.html | 0001213900-26-077542 |
| Document: 0001213900-26-077542.txt | 0001213900-26-077542 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.74%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.45%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.31%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers